CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...
An exciting enhancement is implementing January 20, 2020 in our Special Testing laboratory as we mov...
As previously mentioned in Zika communications distributed on September 21 and October 12, 2018; ord...
Beginning June 1, 2020 all 5 CTS laboratories will being transitioning from the Grifols Procleix Ult...
National Blood Donor Month has been observed in January since 1970, with the goal of increasing bloo...
That’s just one of the reasons that National Blood Donor Month, which has taken place each Jan...